

## Financial Tear Sheet

### Corporate Profile

PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expert-based contract research, consulting, medical communications, and technology solutions to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc. provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.

#### Corporate Structure

The Company is managed through three business segments: Clinical Research Services (CRS), PAREXEL Consulting Services, and PAREXEL Informatics (PI).

CRS constitutes the Company's core business and includes all phases of clinical research from "first-in-man" trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies. CRS service offerings include clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services.

PAREXEL Consulting Services provides technical expertise and advice in such areas as drug development, regulatory affairs, and good manufacturing practice ("GMP") compliance consulting. In addition, PC provides a full spectrum of market development, product development, commercialization, and targeted communications services in support of product launch. PC consultants also identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues.

PAREXEL Informatics provides information technology solutions designed to improve clients' product development processes. PI's portfolio of products and services includes ClinPhone RTSM, medical imaging services, RIM, CTMS, EDC, web-based portals, systems integration, and patient diary applications. These solutions are sold individually or in combination, as elements of an eClinical suite.

## Stock Quote

### PRXL (Common Stock)

---

Exchange	NASDAQ (US Dollar)
Price	\$86.80
Change (%)	▼ 0.31 (0.36%)
Volume	2,781,625
52 Week Low	\$51.16
Market Cap	\$4,406,166,512
Rolling EPS	2.28
PE Ratio	38.2284
Shares Outstanding	50,762,287

Data as of 06/23/17 4:00 p.m. ET

## Stock Chart



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Recent Press Releases

June 20, 2017

PAREXEL International Enters Definitive Agreement to Be Acquired by Pamplona Capital Management for \$88.10 Per Share in Cash

June 19, 2017

PAREXEL Introduces Its Connected Journey™ of Newly Integrated Data-Driven Services to Simplify Drug Development and Commercialization

June 19, 2017

PAREXEL's Alberto Grignolo Named Fellow by Drug Information Association

## Recent Events

Thursday, June 30, 2016 9:00 a.m. ET  
PAREXEL International Investor Day 2016

## SEC Filings

<u>Filing Date</u>	<u>Form</u>
06/22/17	SC 13D/A
06/22/17	DEFA14A
06/20/17	DEFA14A
06/20/17	8-K

## Contact Information

Ronald Aldridge  
Sr. Director, Investor Relations  
PAREXEL International Corporation  
Phone: +1-781-434-4753  
Email: [IR@parexel.com](mailto:IR@parexel.com)

## Board of Directors

A. Dana Callow, Jr.	Managing General Partner Boston Millennia Partners
Patrick J. Fortune, Ph.D.	Vice President Market Sectors Partners HealthCare
Maykin Ho, Ph.D.	Managing Partner Viridian Global
Eduard E. Holdener, M.D.	Chairman and Chief Executive Officer NovImmune S.A. Emeritus Head of Global Pharmaceutical Development F. Hoffman-La Roche, Ltd.
Christopher J. Lindop	Chief Financial Officer Quotient Limited
Richard L. Love	Managing Partner Translational Accelerator, LLC (TRAC)
Josef H. von Rickenbach	Chairman of the Board and Chief Executive Officer PAREXEL International Corporation
Ellen M. Zane	CEO Emeritus Vice Chair, Board of Trustees Tufts Medical Center